Form 6-K Summary
Registrant: NLS Pharmaceutics Ltd. The request metadata identifies Newcelx Ltd., but the filing names NLS Pharmaceutics Ltd. as the registrant.
Reporting period: December 2022; filed December 8, 2022. The filing reports a private placement transaction announced on December 6, 2022.
Business Context and Transaction
The company entered into a securities purchase agreement with funds affiliated with BVF Partners L.P. to finance development of its lead product, Quilience® (Mazindol ER), for narcolepsy, business development and licensing activities, and general corporate purposes.
- First closing: Issuance of 5,747,126 common shares and pre-funded warrants to purchase 5,747,127 additional common shares.
- Price: $0.87 per common share or pre-funded warrant.
- Gross proceeds: $10 million, with the first closing expected on December 13, 2022, subject to customary conditions.
- Potential second closing: BVF may purchase up to $20 million of units at $1.50 per unit through the applicable election deadline, defined by reference to 30 days after receipt of official written minutes from the company’s Phase 2 FDA meeting.
Financial Metrics and Capital Structure
- The filing does not provide revenue, profit, operating cash flow, margins, cash balance, debt, or liquidity metrics.
- The first closing is expected to provide $10 million of gross cash proceeds; net proceeds were not quantified.
- Second-closing proceeds are contingent and may be up to $20 million.
- For the second closing, BVF would also receive warrants to purchase up to 150% of the shares or pre-funded warrant shares purchased, with a five-year term and a $2.03 exercise price per share.
- The transaction will increase the company’s outstanding shares and may result in additional dilution upon exercise of the pre-funded warrants and other warrants.
Material Changes and Terms
- The company granted BVF participation rights in future securities offerings through the earlier of 30 months after the initial closing or the date BVF’s beneficial ownership falls below 9.9%.
- BVF received the right to nominate one director, subject to the same ownership-related termination condition.
- The company agreed to restrictions on new equity or equity-equivalent issuances until the earlier of specified periods following the election deadline or second closing, or February 28, 2023, subject to exceptions.
- The company agreed to file an SEC resale registration statement for the securities purchased or to be purchased within 30 days after the first closing.
- The company intends to seek shareholder approval to increase ordinary, conditional, and/or authorized share capital to permit the second closing. Certain shareholders agreed to vote in favor of the proposal.
Outlook, Risks, and Unusual Items
- The second closing is not assured and depends on BVF’s election, shareholder approval, available share capital, and other closing conditions.
- Development of Quilience® remains subject to clinical, regulatory, financing, and commercialization risks. The filing does not provide a specific FDA meeting outcome or development timetable.
- The securities were sold in a private placement under Section 4(a)(2) and Rule 506(b) of Regulation D and were not registered under the Securities Act or applicable state securities laws.
- Resale of the securities is restricted absent an effective registration statement or an available exemption.
- The filing incorporates the transaction documents and warrant forms as Exhibits 99.1 through 99.3.
Investor Verification Checklist
- Confirm that the first closing occurred and determine the actual net proceeds received.
- Verify the company’s cash balance, liquidity runway, debt obligations, and use of proceeds in subsequent filings.
- Check whether the second closing was exercised, whether shareholder approval was obtained, and the resulting share count and dilution.
- Review the official minutes and outcome of the Phase 2 FDA meeting and any subsequent development updates for Quilience®.
- Review the warrant terms, beneficial ownership limitations, resale registration status, and BVF’s board nomination and participation rights.